The effect of alpha methyldopa and spironolactone on angiotensin sensitivity in man
Káldor, A.; Kállay, K.; Sebestyén, K.; Alexits, K.
Orvosi Hetilap 113(1): 23-24
1972
ISSN/ISBN: 0030-6002 PMID: 4333395 Document Number: 56163
Document emailed within 1 workday
Related Documents
Surabenjawong, U.; Thunpiphat, N.; Chatsiricharoenkul, S.; Monsomboon, A. 2013: Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers Journal of the Medical Association of Thailand 96(8): 905-910Uretsky, N.J. 1974: Effect of alpha-methyldopa on the metabolism of dopamine in the striatum of the rat Journal of Pharmacology and Experimental Therapeutics 189(2): 359-369
Erbler, H.C. 1979: Effect of spironolactone and its main metabolite canrenone on the renin-angiotensin-aldosterone-system during long-term treatment in rats Acta Endocrinologica 90(1): 147-156
Hauser, G.J.; Almog, S.; Tirosh, M.; Spirer, Z. 1985: Effect of alpha-methyldopa excreted in human milk on the breast-fed infant Helvetica Paediatrica Acta 40(1): 83-86
Adithan, C.; Venkataraman, B.V.; Joseph, T. 1982: Effect of alpha-Methyldopa on Physostigmine induced pressor response in rats Indian Journal of Experimental Biology 20(11): 842-844
Clineschmidt, B.V.; Flataker, L.M.; Faison, E.P.; Haubrich, D.R. 1980: Alpha-methyldopa reduces locomotor activity in rats via its metabolite, alpha-methylnorepinephrine, acting on alpha 2-adrenoceptors Archives Internationales de Pharmacodynamie et de Therapie 244(2): 231-243
During, R.; Schwarzlos, G. 1985: Effect of alpha-methyldopa (Dopegyt) on blood pressure in hypertensive pregnant patients Zentralblatt für Gynakologie 107(6): 357-362
Carpentiere, G.; Castello, F.; Marino, S. 1984: Effect of alpha-methyldopa in single and divided doses on the circadian rhythm of arterial pressure in hypertensive patients La Clinica Terapeutica 108(6): 497-502
Greenberg, S. 1981: Effect of chronic administration of clonidine, propranolol and alpha-methyldopa on extensibility and biochemical properties of the veins in renal and spontaneous hypertension Journal of Pharmacology and Experimental Therapeutics 218(3): 779-790
Kállay, K.; Káldor, A.; Gachályi, B.; Sebestyén, K.; Földvári, A. 1974: The effect of guanethidine and reserpine in angiotensin sensitivity in man Orvosi Hetilap 115(49): 2917-2919
Bendtzen, K.; Hansen, P.R.; Rieneck, K. 2004: Spironolactone inhibits production of proinflammatory cytokines, including tumor necrosis factor-alpha and interferon-gamma and has potential effect in the treatment of arthritis Ugeskrift for Laeger 166(37): 3203-3207
Gachályi, B.; Káldor, A.; Kállay, K. 1975: The effect of propranolol on plasma renin level and angiotensin sensitivity in man Orvosi Hetilap 116(27): 1570-1571
Taylor, P.; Gillman, P.K.; Gaind, R. 1978: Alpha-methyldopa in schizophrenia Journal of Clinical Psychiatry 39(11): 815-816
Farsang, C. 1986: Update on alpha-methyldopa Therapia Hungarica 34(3): 139-149
Kaplinsky, N.; Fraenkel, O. 1972: Hemolytic anemia due to alpha-methyldopa Harefuah 83(11): 487-488
Aubert, J.F.; Waeber, B.; Nussberger, J.; Vavrek, R.; Stewart, J.M.; Brunner, H.R. 1987: Attenuation of the vasopressor effect of angiotensin II, vasopressin and alpha 1-adrenergic stimulation by bradykinin Archives des Maladies du Coeur et des Vaisseaux 80(6): 832-834
Koller, O.; Lehoczky, D. 1976: Immune hemolysis in the course of alpha methyldopa therapy Orvosi Hetilap 117(9): 545-546
Uspenskiĭ, A.E.; Korobov, N.V. 1976: Facilitation of the effects of L-DOPA by alpha-methyldopa Biulleten' Eksperimental'noi Biologii i Meditsiny 81(3): 314-316
Qadri, F.; Culman, J.; Veltmar, A.; Maas, K.; Rascher, W.; Unger, T. 1993: Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin Ii AT1 receptors in the supraoptic nucleus Journal of Pharmacology and Experimental Therapeutics 267(2): 567-574
Chouinard, G.; Pinard, G.; Prenoveau, Y.; Tetreault, L. 1973: Alpha methyldopa-chlorpromazine interaction in schizophrenic patients Current Therapeutic Research 15(2): 60-72